|
|
|
| Value of RASSF1A gene methylation combined with plasma MYC antibody for diagnosing cervical cancer |
| Yinzhou People's Hospital, Ningbo, Zhejiang Province, 315040 |
|
|
|
|
Abstract To investigate the value of the methylation of RA-related regional families 1A (RASSF1A) gene combined with plasma MYC antibody for diagnosing cervical cancer. Methods: 64 women with cervical cancer were selected in study group from January 2017 to June 2018, and 45 healthy women were selected in control group during the same period. Nested methylation specific PCR (nMSP) was used to detect the methylation status of RASSF1A gene of women in the two groups, and the level of plasma MYC antibody was detected by enzyme-linked immunosorbent assay (ELISA). The value of detection and diagnosis the methylation status of RASSF1A gene and plasma MYC antibody level for cervical cancer was analyzed. Results: There were 31 (48.4%) women with promoter methylation of RASSF1A gene in the study group, while there were no woman with promoter methylation of RASSF1A gene, which had significant difference between the two groups (P＜0.05). The plasma MYC antibody level of women in the study group was significant higher than that of women in control group (P＜0.05). Methylation of RASSF1A gene of women with cervical cancer was related to their clinical stage and lymph node metastasis, and plasma MYC antibody level of women with cervical cancer was related to clinical stage and tumor diameter (all P＜0.05). The area under the curve, the sensitivity, and the specificity of plasma MYC antibody level for diagnosing cervical cancer were 0.611, 35.9%, and 84.4%, respectively. Conclusion: Methylation of RASSF1A gene combined with plasma MYC antibody level for diagnosing cervical cancer has some clinical value.
|
|
|
|
|
|
|
|
|
